Adverum Biotechnologies Inc (ADVM)
7.525
+0.12
(+1.55%)
USD |
NASDAQ |
Nov 04, 16:00
7.53
0.00 (0.00%)
Pre-Market: 20:00
Adverum Biotechnologies Free Cash Flow: -89.12M for June 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2024 | -89.12M |
| March 31, 2024 | -92.55M |
| December 31, 2023 | -91.71M |
| September 30, 2023 | -88.85M |
| June 30, 2023 | -97.07M |
| March 31, 2023 | -109.10M |
| December 31, 2022 | -119.91M |
| September 30, 2022 | -131.41M |
| June 30, 2022 | -130.30M |
| March 31, 2022 | -132.55M |
| December 31, 2021 | -122.95M |
| September 30, 2021 | -116.44M |
| June 30, 2021 | -114.56M |
| March 31, 2021 | -97.02M |
| December 31, 2020 | -91.14M |
| September 30, 2020 | -90.69M |
| June 30, 2020 | -76.78M |
| March 31, 2020 | -70.84M |
| December 31, 2019 | -68.42M |
| September 30, 2019 | -58.10M |
| June 30, 2019 | -59.54M |
| March 31, 2019 | -56.98M |
| Date | Value |
|---|---|
| December 31, 2018 | -54.77M |
| September 30, 2018 | -54.18M |
| June 30, 2018 | -47.18M |
| March 31, 2018 | -47.56M |
| December 31, 2017 | -46.44M |
| September 30, 2017 | -43.41M |
| June 30, 2017 | -43.24M |
| March 31, 2017 | -40.58M |
| December 31, 2016 | -40.78M |
| September 30, 2016 | -40.83M |
| June 30, 2016 | -41.36M |
| March 31, 2016 | -42.45M |
| December 31, 2015 | -38.33M |
| September 30, 2015 | -34.44M |
| June 30, 2015 | -28.97M |
| March 31, 2015 | -13.35M |
| December 31, 2014 | -6.591M |
| September 30, 2014 | -1.902M |
| June 30, 2014 | 2.585M |
| March 31, 2014 | -3.438M |
| December 31, 2013 | -2.266M |
Free Cash Flow Range, Past 5 Years
-132.55M
Minimum
Mar 2022
-68.42M
Maximum
Dec 2019
-101.65M
Average
-97.02M
Median
Mar 2021
Free Cash Flow Benchmarks
| EyePoint Pharmaceuticals Inc | -94.36M |
| Cassava Sciences Inc | -86.31M |
| Regenxbio Inc | -194.72M |
| Editas Medicine Inc | -171.54M |
| Apellis Pharmaceuticals Inc | -408.81M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -19.84M |
| Cash from Investing (Quarterly) | -2.327M |
| Cash from Financing (Quarterly) | -0.116M |
| Free Cash Flow Per Share (Quarterly) | -0.9524 |
| Free Cash Flow Yield | -82.31% |